Today: 21 March 2026
Subscribe
Browse Category

NYSE:KVUE 9 November 2025 - 20 January 2026

Kenvue stock ticks up as investors size up Kimberly-Clark takeover vote in days

Kenvue stock ticks up as investors size up Kimberly-Clark takeover vote in days

Kenvue shares rose 0.6% to $17.31 in late-morning New York trading Tuesday as investors awaited a Jan. 29 shareholder vote on its proposed sale to Kimberly-Clark. The deal’s outcome remains uncertain amid ongoing litigation risks tied to Kenvue’s legacy products. ISS has backed the merger but flagged legal concerns. Kenvue’s virtual shareholder meeting is scheduled for 9:00 a.m. Eastern on Jan. 29.
20 January 2026
··
Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next

Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next

Johnson & Johnson shares closed down 0.4% at $218.66 Friday ahead of the Martin Luther King Jr. Day market holiday. The S&P 500 health care sector fell 0.8%. J&J reports fourth-quarter results Wednesday, Jan. 21, with investors focused on earnings and 2026 guidance. The NYSE will reopen Tuesday after the holiday.
18 January 2026
·······
Kenvue stock has a new catalyst: ISS backs Kimberly-Clark merger ahead of Jan. 29 vote

Kenvue stock has a new catalyst: ISS backs Kimberly-Clark merger ahead of Jan. 29 vote

Kenvue shares closed at $17.20 Friday, down 0.35%, ahead of a Jan. 29 shareholder vote on its sale to Kimberly-Clark. Proxy adviser ISS recommended investors back the deal but cited ongoing legal and market risks. Kenvue updated merger disclosures after lawsuits challenged the process. The offer values Kenvue at about $18.03 per share, a 4.6% premium to Friday’s close.
18 January 2026
··
Kenvue stock edges up as Kimberly-Clark vote nears — the deal spread traders are watching

Kenvue stock edges up as Kimberly-Clark vote nears — the deal spread traders are watching

Kenvue shares rose 0.4% to $17.08 in mid-morning trading after Kimberly-Clark filed new deal documents with U.S. regulators. The stock remains about 5% below the value implied by the pending cash-and-stock takeover. Kenvue shareholders are set to vote on the deal Jan. 29. The transaction’s value fluctuates with Kimberly-Clark’s share price.
14 January 2026
···
Kenvue (KVUE) stock nudges up as fresh deal scrutiny hits — and the spread traders are watching

Kenvue (KVUE) stock nudges up as fresh deal scrutiny hits — and the spread traders are watching

Kenvue shares rose 0.8% to $16.87 Thursday after law firm Kahn Swick & Foti said it is investigating the company’s pending sale to Kimberly-Clark. The offer values Kenvue at about $17.91 per share, a 6% premium to Thursday’s price. Shareholders are set to vote on the deal in late January. Kenvue also named Madhav Nayak as vice president and chief marketing officer for Asia-Pacific.
8 January 2026
··
Kenvue Stock (NYSE: KVUE) News Today: Kimberly-Clark Deal Update, Insider Buying, Analyst Forecasts — December 25, 2025

Kenvue Stock (NYSE: KVUE) News Today: Kimberly-Clark Deal Update, Insider Buying, Analyst Forecasts — December 25, 2025

Kenvue shares closed December 24 at $17.21, up 1.12% in light holiday trading, as investors weigh Kimberly-Clark’s pending acquisition. The agreed deal values KVUE at about $18.28 per share based on current KMB prices, but the stock trades below that level amid regulatory, timing, and legal uncertainties. The transaction is expected to close in the second half of 2026.
25 December 2025
··
Kenvue Stock (KVUE) News, Forecasts and Analysis for December 23, 2025: Deal Math, Legal Headlines, and What Investors Are Watching

Kenvue Stock (KVUE) News, Forecasts and Analysis for December 23, 2025: Deal Math, Legal Headlines, and What Investors Are Watching

A Baltimore jury ordered Johnson & Johnson and spinoff Kenvue to pay over $1.5 billion in a talc cancer case, with J&J saying it will appeal. Kenvue shares traded at $16.98, about $1.15 below the implied $18.12 merger value based on Kimberly-Clark’s price, reflecting deal risk. The acquisition is expected to close in the second half of 2026. J&J has said it will cover Kenvue’s talc liabilities.
23 December 2025
···
Kenvue Stock (KVUE) News Today: Deal Spread Math, Kimberly-Clark Vote Timeline, Tylenol Lawsuits, and Analyst Forecasts (Dec. 19, 2025)

Kenvue Stock (KVUE) News Today: Deal Spread Math, Kimberly-Clark Vote Timeline, Tylenol Lawsuits, and Analyst Forecasts (Dec. 19, 2025)

Kenvue shares closed at $17.10 on Dec. 19, 2025, down 1.04% amid heavy trading. Kimberly-Clark’s pending cash-and-stock acquisition values Kenvue at about $18.35 per share, based on current prices, leaving a deal spread of roughly 7%. The merger awaits shareholder and regulatory approval, with legal risks and earnings pressure influencing the stock.
19 December 2025
··
Kenvue Stock (KVUE) Today: Latest News, Deal Outlook, Analyst Forecasts and Key Risks (Dec. 15, 2025)

Kenvue Stock (KVUE) Today: Latest News, Deal Outlook, Analyst Forecasts and Key Risks (Dec. 15, 2025)

Kenvue shares traded near $17.33 midday Monday, about 7% below the implied $18.59 value of Kimberly-Clark’s pending cash-and-stock offer. The gap reflects market uncertainty as the $48.7 billion deal awaits regulatory and shareholder approval, with closing expected in the second half of 2026. Kimberly-Clark shares stood at $103.15. New legal filings and shareholder law firm activity surfaced Monday.
15 December 2025
··
KVUE Stock Today (Nov. 22, 2025): Kenvue Rises as Kimberly‑Clark Deal, Dividend and Tylenol Ruling Shape Outlook

KVUE Stock Today (Nov. 22, 2025): Kenvue Rises as Kimberly‑Clark Deal, Dividend and Tylenol Ruling Shape Outlook

Kenvue shares closed at $16.64 in late Friday trading, up 3% on heavy volume, but still about 12% below the value implied by Kimberly-Clark’s takeover offer. The deal, announced November 3 and valued at $48–49 billion, would pay Kenvue holders $3.50 in cash plus 0.14625 KMB shares per KVUE share. Both boards approved the merger, expected to close in the second half of 2026.
22 November 2025
·
Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

KVUE Stock Today (Nov. 18, 2025): Shares Slip as Appeals Court Weighs Tylenol Cases; Dividend Cleared; Kimberly‑Clark Deal Spread Persists

Kenvue shares traded near $16.13 midday, down 0.7%, after a U.S. appeals court signaled it may revive over 500 Tylenol-autism lawsuits. A Texas judge declined to block Kenvue’s $398 million dividend, which remains set for Nov. 26. The pending Kimberly-Clark deal implies $18.83 per share for KVUE, about 14% above its current price. Volume reached 21.1 million shares by 17:32 UTC.
18 November 2025
·····
1 2 3

Stock Market Today

  • Is Disney Stock Fairly Valued Amid Recent Price Weakness?
    March 21, 2026, 1:51 AM EDT. Disney (DIS) shares have recently weakened, closing at $99.51 with a 7.1% drop over 30 days and 11% year-to-date decline. Over five years, the stock is down 45.2%. Despite mixed performance, Disney's valuation scores 5 out of 6 on Simply Wall St's metrics. A Discounted Cash Flow (DCF) model estimates Disney's intrinsic value at $99.89, nearly matching its current price, suggesting the stock is fairly valued with a slight 0.4% undervaluation. The DCF uses projected free cash flows rising to $14.10 billion by 2030, emphasizing Disney's long-term cash generation prospects. Investors should monitor Disney's valuation as cash flow estimates and market conditions evolve. The P/E ratio and other traditional metrics also provide context for assessing Disney's price relative to earnings and growth expectations.
Go toTop